Adding weight to a sinking ship: more reasons not to perform routine surveillance imaging in patients with diffuse large B-cell lymphoma in remission

References

• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817–1826.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525–533.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008;93:1837–1842.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Obuchowski NA, Graham RJ, Baker ME, et al. Ten criteria for effective screening: their application to multislice CT screening for pulmonary and colorectal cancers. AJR Am J Roentgenol 2001;176:1357–1362.
   PubMed Web of Science ®Google Scholar
• Hong J, Kim JH, Lee KH, et al. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2014;55:2312–2318.
   PubMed Web of Science ®Google Scholar
• Elis A, Blickstein D, Klein O, et al. Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. Am J Hematol 2002;69:41–44.
   PubMed Web of Science ®Google Scholar
• Guppy AE, Tebbutt NC, Norman A, et al. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:123–125.
   PubMed Web of Science ®Google Scholar
• Lin TL, Kuo MC, Shih LY, et al. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Ann Hematol 2012;91:1741–1745.
   PubMed Web of Science ®Google Scholar
• Weeks JC, Yeap BY, Canellos GP, et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991;9:1196–1203.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Hofman MS, Dickinson M, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 2013;109:312–317.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Charlson ME, Schenkein E, et al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 2010;21:2262–2266.
   PubMed Web of Science ®Google Scholar
• Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009;251: 166–174.
   PubMed Web of Science ®Google Scholar
• Murano T, Minamimoto R, Senda M, et al. Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey. Ann Nucl Med 2011;25:657–666.
   PubMed Web of Science ®Google Scholar
• Hasebroock KM, Serkova NJ. Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol 2009;5:403–416.
   PubMed Web of Science ®Google Scholar
• Abel GA, Vanderplas A, Rodriguez MA, et al. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma 2012;53:1113–1116.
   PubMed Web of Science ®Google Scholar
• Avivi I, Zilberlicht A, Dann EJ, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol 2013;88: 400–405.
   PubMed Web of Science ®Google Scholar
• El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica 2012;97:931–936.
   PubMed Web of Science ®Google Scholar
• Goldschmidt N, Or O, Klein M, et al. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol 2011;90:165–171.
   PubMed Web of Science ®Google Scholar
• Petrausch U, Samaras P, Haile SR, et al. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010;21:1694–1698.
   PubMed Web of Science ®Google Scholar
• Truong Q, Shah N, Knestrick M, et al. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. Clin Lymphoma Myeloma Leuk 2014;14:50–55.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781–1787.
   PubMed Web of Science ®Google Scholar
• El-Galaly T, Prakash V, Christiansen I, et al. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma 2011;52:597–603.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989–1996.
   PubMed Web of Science ®Google Scholar
• Perales MA, Jenq R, Goldberg JD, et al. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant 2010;45:1408–1416.
   PubMed Web of Science ®Google Scholar
• Liedtke M, Hamlin PA, Moskowitz CH, et al. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006;17:909–913.
   PubMed Web of Science ®Google Scholar
• American Society of Hematology. Five things physicians and patients should question. In: Choosing Wisely. 2014. Available from: www.choosingwisely.org/doctor-patient-lists/american-society-of-hematology%3E
   Google Scholar
• Schnipper LE, Lyman GH, Blayney DW, et al. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol 2013;31:4362–4370.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Wierda WG, Abramson JS, et al. Non-Hodgkin's lymphoma Version 1.2014. In NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. 2014. Available from: www.nccn.org/professionals/physician_gls/f_guidelines.asp%3E
   Google Scholar
• El-Sharkawi D, Basu S, Ocampo C, et al. Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy. Leuk Lymphoma 2012;53:1949–1952.
   PubMed Web of Science ®Google Scholar
• William BM, Bongu NR, Bast M, et al. The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter 2013;35:189–191.
   PubMedGoogle Scholar
• Hong J, Yoon HH, Ahn HK, et al. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma. Acta Haematol 2013;130:305–311.
   PubMed Web of Science ®Google Scholar
• Bratman S, Liu CL, Takahashi K, et al. Utility Of non-invasive monitoring of circulating tumor DNA at diagnosis, interim therapy, and relapse of DLBCL using high-throughput sequencing of immunoglobulin genes. Blood 2013;122(Suppl. 1): Abstract 4264.
   PubMed Web of Science ®Google Scholar